224.41
0.47 (0.21%)
| Penutupan Terdahulu | 223.94 |
| Jumlah Dagangan | 1,064,035 |
| Harga / Pendapatan (P/E Ke hadapan) | 19.68 |
| Harga / Jualan (P/S) | 7.27 |
| Harga / Buku (P/B) | 24.87 |
| Julat 52 Minggu |
| Margin Keuntungan | -11.49% |
| Margin Operasi (TTM) | 3.04% |
| EPS Cair (TTM) | -2.11 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 20.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2,358.25% |
| Nisbah Semasa (MRQ) | 3.04 |
| Aliran Tunai Operasi (OCF TTM) | -45.11 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 223.09 M |
| Pulangan Atas Aset (ROA TTM) | -1.79% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Alnylam Pharmaceuticals, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | 3.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -2.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | 2.5 |
| AI Insight | NA |
| Purata | 0.06 |
|
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam’s commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam’s partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 3.81% |
| % Dimiliki oleh Institusi | 97.56% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| SUPRAN BRYAN | - | 219.72 | -1,758 | -386,268 |
| Jumlah Keseluruhan Kuantiti Bersih | -1,758 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -386,268 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 219.72 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| SUPRAN BRYAN | Pegawai | 02 Oct 2026 | Jual (-) | 1,758 | 219.72 | 386,268 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |